Merck & Co., Inc. Other Comprehensive Income (Loss), before Reclassifications, Net of Tax
Merck & Co., Inc. (MRK) reported Other Comprehensive Income (Loss), before Reclassifications, Net of Tax of $20.00 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-24.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax · last filed 2023-02-24
- Merck & Co., Inc. other comprehensive income (loss), before reclassifications, net of tax for the quarter ending 2015-06-30 was -$73.00M.
- Merck & Co., Inc. other comprehensive income (loss), before reclassifications, net of tax for the quarter ending 2015-03-31 was $276.00M, a 1625.00% increase year-over-year.
- Merck & Co., Inc. other comprehensive income (loss), before reclassifications, net of tax for the quarter ending 2014-12-31 was -$1.27B, a 152.19% decline year-over-year.
- Merck & Co., Inc. other comprehensive income (loss), before reclassifications, net of tax for the quarter ending 2014-09-30 was -$556.00M, a 5660.00% decline year-over-year.
- Merck & Co., Inc. other comprehensive income (loss), before reclassifications, net of tax for fiscal 2022 was $20.00M, a 98.39% decline from fiscal 2021.
- Merck & Co., Inc. other comprehensive income (loss), before reclassifications, net of tax for fiscal 2021 was $1.24B.
- Merck & Co., Inc. other comprehensive income (loss), before reclassifications, net of tax for fiscal 2020 was -$656.00M.
- Merck & Co., Inc. other comprehensive income (loss), before reclassifications, net of tax for fiscal 2019 was -$449.00M.
| Period end | Other Comprehensive Income (Loss), before Reclassifications, Net of Tax 3 month | Other Comprehensive Income (Loss), before Reclassifications, Net of Tax 6 month | Other Comprehensive Income (Loss), before Reclassifications, Net of Tax 9 month | Other Comprehensive Income (Loss), before Reclassifications, Net of Tax 12 month | Other Comprehensive Income (Loss), before Reclassifications, Net of Tax 12 month as first filed |
|---|---|---|---|---|---|
| 2022-12-31 | $20.00M 10-K · filed 2023-02-24 | ||||
| 2021-12-31 | $1.24B 10-K · filed 2023-02-24 | $1.38B 10-K · filed 2022-02-25 | |||
| 2020-12-31 | -$656.00M 10-K · filed 2023-02-24 | -$631.00M 10-K · filed 2021-02-25 | |||
| 2019-12-31 | -$449.00M 10-K · filed 2022-02-25 | ||||
| 2018-12-31 | -$716.00M 10-K · filed 2021-02-25 | ||||
| 2017-12-31 | $556.00M 10-K · filed 2020-02-26 | ||||
| 2015-06-30 | -$73.00M 10-Q · filed 2015-08-06 | $203.00M 10-Q · filed 2015-08-06 | -$1.07B derived: sum of 3 quarters · filed 2015-08-06 | -$1.63B derived: sum of 4 quarters · filed 2015-08-06 | |
| 2015-03-31 | $276.00M 10-Q · filed 2015-05-07 | -$998.00M derived: sum of 2 quarters · filed 2015-05-07 | -$1.55B derived: sum of 3 quarters · filed 2015-05-07 | -$1.85B derived: sum of 4 quarters · filed 2015-08-06 | |
| 2014-12-31 | -$1.27B derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-27 | -$1.83B derived: sum of 2 quarters · filed 2015-02-27 | -$2.13B derived: sum of 3 quarters · filed 2015-08-06 | -$2.11B 10-K · filed 2015-02-27 | |
| 2014-09-30 | -$556.00M 10-Q · filed 2014-11-10 | -$851.00M derived: sum of 2 quarters · filed 2015-08-06 | -$835.00M 10-Q · filed 2014-11-10 | $1.61B derived: sum of 4 quarters · filed 2015-08-06 | |
| 2014-06-30 | -$295.00M 10-Q · filed 2015-08-06 | -$279.00M 10-Q · filed 2015-08-06 | $2.16B derived: sum of 3 quarters · filed 2015-08-06 | $2.17B derived: sum of 4 quarters · filed 2015-08-06 | |
| 2014-03-31 | $16.00M 10-Q · filed 2015-05-07 | $2.46B derived: sum of 2 quarters · filed 2015-05-07 | $2.47B derived: sum of 3 quarters · filed 2015-05-07 | $2.29B derived: sum of 4 quarters · filed 2015-05-07 | |
| 2013-12-31 | $2.44B derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-27 | $2.45B derived: sum of 2 quarters · filed 2015-02-27 | $2.28B derived: sum of 3 quarters · filed 2015-02-27 | $2.28B 10-K · filed 2015-02-27 | |
| 2013-09-30 | $10.00M 10-Q · filed 2014-11-10 | -$164.00M derived: sum of 2 quarters · filed 2014-11-10 | -$159.00M 10-Q · filed 2014-11-10 | ||
| 2013-06-30 | -$174.00M 10-Q · filed 2014-08-07 | -$169.00M 10-Q · filed 2014-08-07 | |||
| 2013-03-31 | $5.00M 10-Q · filed 2014-05-08 | ||||
| 2012-12-31 | -$1.64B 10-K · filed 2015-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |